Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.1 EUR | -3.94% | -0.81% | +44.55% |
Apr. 26 | Agronomics investee raises additional EUR8 million | AN |
Apr. 26 | Agronomics' Portfolio Company Raises Additional EUR8 Million for New Protein Product | MT |
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company returns high margins, thereby supporting business profitability.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 55.45 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Sector: Investment Management & Fund Operators
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+44.55% | 38.61M | - | ||
+20.18% | 38.38B | B | ||
+1.36% | 36.11B | B | ||
0.00% | 20.42B | - | - | |
+6.99% | 5.44B | - | C | |
+4.24% | 4.15B | D+ | ||
+3.23% | 3.3B | - | B- | |
+24.41% | 3.03B | C- | ||
-8.52% | 2.62B | C+ | ||
+3.52% | 1.23B | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- SPRING Stock
- Ratings Springvest Oyj